These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18281559)

  • 21. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
    Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
    Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukemia regression by vascular disruption and antiangiogenic therapy.
    Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
    Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
    Salnikov AV; Heldin NE; Stuhr LB; Wiig H; Gerber H; Reed RK; Rubin K
    Int J Cancer; 2006 Dec; 119(12):2795-802. PubMed ID: 17019708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.
    Mizobe T; Ogata Y; Murakami H; Akagi Y; Ishibashi N; Mori S; Sasatomi T; Shirouzu K
    Oncol Rep; 2008 Sep; 20(3):517-23. PubMed ID: 18695900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
    Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
    Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
    Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
    J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
    Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
    Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease.
    Sims TL; Williams RF; Ng CY; Rosati SF; Spence Y; Davidoff AM
    Surgery; 2008 Aug; 144(2):269-75. PubMed ID: 18656635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
    Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
    Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
    Liu W; Xu J; Wang M; Wang Q; Bi Y; Han M
    Int J Oncol; 2011 Nov; 39(5):1213-20. PubMed ID: 21785819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
    Finn RS; Bentley G; Britten CD; Amado R; Busuttil RW
    Liver Int; 2009 Feb; 29(2):284-90. PubMed ID: 18482274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms.
    Stollman TH; Scheer MG; Franssen GM; Verrijp KN; Oyen WJ; Ruers TJ; Leenders WP; Boerman OC
    Cancer Biother Radiopharm; 2009 Apr; 24(2):195-200. PubMed ID: 19409041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.